Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug in early symptomatic Alzheimer's disease (China, Phase 3)
CTR20230358Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of remternetug in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Feb 2023; status: terminated.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20230358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230358.